Skip to main content
. 2016 Oct 31;49(3):748–758. doi: 10.4143/crt.2016.303

Table 2.

Univariate and multivariate analysis for lLMCDM-FS

Characteristic No. of patients Univariate analysis
Multivariate analysis
18-Month LMCDM-FS (%) p-valuea) Hazard ratiob) 95% CI p-valuec)
Extracranial disease status
 None or stable 35 42.1 0.113
 Progressive 16 64.8
Biological subtype of primary tumor
 ER+ and/or PR+, HER2− 7 53.6 0.882
 HER2-positive 19 44.1
 Triple negative 13 58.3
No. of brain metastases
 1 36 45.1 0.191
 2-3 15 60.0
Size (cm)
 < 3.5 23 51.3 0.906
 ≥ 3.5 27 41.1
Adjacent to CSF flowd)
 No 10 80.0 0.050 1.0 - -
 Yes 40 40.3 2.3 0.4-13.5 0.456
Extent of resection
 GTR 40 42.6 0.120
 STR 11 71.4
Systemic treatment after brain surgery and before the development of LMCDM
 No 21 8.0 < 0.001 1.0 - -
 Targeted Tx±CTx 13 69.8 0.1 0.0-0.3 < 0.001
 CTx 17 67.5 0.1 0.0-0.3 < 0.001
Postoperative RT
 WBRT 24 77.5 0.013 1.0 - -
 PRT 10 30.0 5.2 1.9-14.8 0.009
 No RT 17 13.6 2.7 0.9-7.9 0.122
Postoperative WBRT
 Yes 24 77.5 0.004
 No 27 22.6
WBRT dose−fractionation
 25 Gy/10 fx 9 65.6 0.945
 30 Gy/12 fx 6 100.0
 30 Gy/10 fx 9 71.4

LMCDM-FS, leptomeningeal carcinomatosis or dural metastasis–free survival; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CSF, cerebrospinal fluid; GTR, gross total resection; STR, subtotal resection; Tx, therapy; CTx, chemotherapy; RT, radiotherapy; WBRT, whole brain radiotherapy; PRT, partial radiotherapy; fx, fractions.

a)

Log-rank test,

b)

Hazard ratio refers to the risk of leptomeningeal carcinomatosis or dural metastasis per unit time,

c)

Cox proportional hazard model (backward likelihood ratio),

d)

n=50 (WBRT, 23; PRT, 10; no RT, 17).